Brief: Conduit Pharmaceuticals Selects Initial Indications For Lead Clinical Candidate Targeting Autoimmune Disorders

CDT Equity

12/08/2024 12:44

Aug 12 (Reuters) - Conduit Pharmaceuticals Inc  CDT.O :
    * CONDUIT PHARMACEUTICALS SELECTS INITIAL INDICATIONS FOR
LEAD
CLINICAL CANDIDATE TARGETING AUTOIMMUNE DISORDERS
    * CONDUIT PHARMACEUTICALS- PLANS TO INITIATE PHASE 2A TRIALS
IN
BOTH SYSTEMIC LUPUS ERYTHEMATOSUS AND ANCA-ASSOCIATED VASCULITIS
FOR AZD1656

Source text for Eikon:  ID:nGNX5CGrDW 
Further company coverage:  CDT.O 

 (Reuters.Briefs@thomsonreuters.com)